Primary Healthcare Practitioners’ Knowledge, Attitude, and Practice Toward Systemic Lupus Erythematosus in the Qassim Region, Saudi Arabia

Mousa N. Alrashdi 1, Sami M. Alrasheedi 1, Ahmad Alkhdaïri 1, Faisal N. Alburaaq 2, Almutairi E. Muteb 2, Abdulaziz S. Alshamikh 2, Khalid Almutairi 1, Almutairi N. Ammar 2, Almutairi L. Saleh 2, Alfurayhidi W. Nawaf 2

1. Department of Medicine, Unaizah College of Medicine and Medical Sciences, Qassim University, Unaizah, SAU
2. Internal Medicine, Qassim University, Unaizah, SAU
3. College of Medicine, Qassim University, Unaizah, SAU

Corresponding author: Mousa N. Alrashdi, mosa4444@hotmail.com

Abstract

Objective

The study aims to evaluate the primary healthcare practitioner’s (PHCP) knowledge, attitude, and practice toward systemic lupus erythematosus (SLE) and to explore the difficulties of early referral to specialized clinics.

Method

This is a cross-sectional study conducted between February and March 2022 targeting the PHCP among the primary healthcare centers in Qassim, Saudi Arabia. The study was conducted among 203 participants who enrolled via a cluster random sampling technique depending on the survey. Qualitative categorical variables are expressed as frequencies and percentages, while continuous variables are reported as means and standard deviations (SD). The one-way analysis of variance (ANOVA) test and the independent T-test have been used to explore the relationship between participants’ knowledge scores and their socio-demographic characteristics. A P-value ≤0.05 was considered statistically significant.

Result

The study found that only 4.4% of participating PHCPs had good knowledge related to SLE, while 45.8% of them had fair knowledge, and nearly half of them (49.8%) had poor knowledge. It was noted that GPs who specialized in family medicine or saw more than 40 patients each week had comparably better knowledge than others, which was statistically significant (p<0.05). The difficulty in diagnosing SLE patients was mentioned by 48.3% of the PHCPs. Family medicine consultants (p<0.001), those who worked in a tertiary care facility for more than six months (p<0.001) and those who worked in a rheumatology department (p<0.05), reported considerably better levels of comfort when treating SLE patients.

Conclusion

This study found that included participants’ understanding of SLE, its diagnosis, and management was inadequate. Coordination between rheumatologists and experts from many disciplines at the primary, secondary, and tertiary levels of care is critical for overcoming ambiguities and obstacles in the diagnosis and therapy of SLE patients.

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune multisystem disease that affects the majority of the body organs, producing different clinical manifestations [1]. The estimated prevalence of SLE in the Qassim region of Saudi Arabia was found to be 19.28 per 100,000 people [2]. Patients may exhibit a wide range of systemic manifestations or general symptoms, such as fever, weight changes, and fatigue, as well as more specific cutaneous manifestations such as rash, photosensitivity, discoid rash, and alopecia [3]. Moreover, patients may also present with musculoskeletal symptoms like arthralgia, myalgia, or inflammatory arthritis; hematological involvement (leukopenia, anemia, or thrombocytopenia); renal involvement (lupus nephritis); pulmonary involvement (pleurisy); and central nervous system involvement (headache, psychiatric, and other neurological symptoms) [3,4]. The European League Against Rheumatism (EULAR) and the American College of Rheumatology have established current classification criteria for SLE diagnosis (ACR). The presence of positive anti-nuclear antibodies (ANA) at least once, as well as an additional seven
clinical and three immunologic features expressed as scores ranging from 2 to 10, is necessary for the
diagnosis of SLE [5]. EULAR 2019 updates for SLE treatment recommendations have been developed to
improve long-term patient outcomes; they mainly depend on disease activity and organ involvement, which
include hydroxychloroquine, glucocorticoids, immunosuppressive, and biological agents [6]. It is crucial to
diagnose SLE as early as possible because early detection of SLE patients leads to better clinical results and is
also cost-effective as it lowers expenditures [7]. Despite increased awareness of SLE, the average period from
symptom onset to diagnosis remains about two years [8]. Delays in receiving a definite diagnosis and
commencing immunosuppressive therapy have been associated with poor outcomes in SLE patients with
significant organ involvement [9,10]. Additionally, failure to attain minimum disease activity during the
first six months after diagnosis has also been associated with early damage development [11,12]. Finally,
appropriate therapy can enhance all subscales of quality of life in individuals with early illness over a two-
year period in patients with early disease [13]. Nonetheless, the role of primary healthcare practitioners
(PHCPs) in SLE is increasing since there are still important unmet health demands, such as community-level
diagnosis delays and the high burden of therapy- and disease-related comorbidities. The goal of an
integrated lupus care paradigm, particularly between PHCPs and specialty facilities, should undoubtedly
improve patient consultations and outcomes [14]. It has been noted that general practitioners (GPs)
correctly diagnosed only 11% of SLE cases presented in clinical scenarios, far fewer than rheumatologists
[15]. Furthermore, SLE awareness research in Cotonou, Benin demonstrated that the majority of GPs had
minimal comprehension and awareness of the clinical and diagnostic criteria for SLE, while another study in
China discovered that more than half of them were unaware of SLE [16,17]. Despite several studies on the
Saudi general population’s comprehension of SLE, no studies on PHCPs’ understanding of SLE have been
conducted in the Kingdom of Saudi Arabia (KSA). As a result, the purpose of this study is to assess our
present PHCP’s knowledge and attitude toward diagnosing and managing SLE. Additionally, we look at
potential sources of deficiency and difficulties in these areas.

**Materials And Methods**

**Setting and participants**

This is a cross-sectional study based on a closed, fixed-response interview survey. Interviewees used an
electronic-based questionnaire built using GoogleForms™ and targeting PHCPs in primary healthcare
centers in the Qassim region, KSA. We targeted 205 participants as a sample size that was calculated for a
descriptive study by using EpiInfo™ (Centers for Disease Control and Prevention (CDC), Atlanta, Georgia).
In order to collect the targeted sample, the questionnaire was emailed to 263 physicians. The technique was
a cluster random sampling technique where lists of names and emails of PHCPs who are currently working
in the Qassim region were obtained from the Qassim Health Cluster. Then the physicians were clustered into
groups according to qualification level and finally coded as numbers, which are used to collect data from
each cluster randomly.

**Data collection methods**

A newly developed questionnaire was constructed from three main domains: the first domain includes
demographic data and current practice; the second domain includes 28 questions that assess the knowledge
about SLE subdivided into three sections, which include clinical presentation and organ involvement,
diagnostic competency, and lastly, management plan. The third domain discussed the difficulty faced by
PHCPs in managing and refereeing patients to specialized centers and their suggestions for improvements.

The draft of our initial questionnaire was made in the English language, which had 31 items excluding
sociodemographic characteristics. Three experts, including a biostatistician, assessed the content and face
validity by focused group discussion. This group had several revisions of the questionnaire to make it
relevant and put it through many meetings. The items that did not agree to have face validity and/or content
validity were eliminated. This initial questionnaire was subjected to pilot testing on 20 participants for
validity and reliability. An exploratory factor analysis was performed to check the construct validity of the
questionnaire. Items with a correlation coefficient >0.7 were removed. For reliability analysis, the items with
“uncertain” answers were marked as negative answers. Internal consistency was measured using Cronbach’s
alpha and test-retest reliabilities between the initial and final questionnaires for each item were calculated
using kappa statistics. Cronbach’s alpha, which was calculated along with one-sided 95% CL. A Cronbach’s α
value >0.7 was considered for our questionnaire to be internally consistent.

**Data analysis plan**

The Statistical Package for Social Sciences (SPSS) software version 26 (IBM Corp., Armonk, NY) is used to
code, enter, and analyze data. Quantitative categorical variables are expressed as frequencies and
percentages, while continuous variables are reported as means and standard deviations (SD). There were 28
items that measured knowledge related to SLE, and the total knowledge level of the participants was
Calculated using scores based on the correct responses. For items that had only one option as the correct
answer, participants were allotted a score of 1 for a correct response and a score of 0 for a wrong response.
For items that had multiple options as correct answers, score 1 was divided by the number of correct options.
For example, if there are four correct answers for an item, the participants get a full score of one if they
choose all four correct options; they get a 0.75 score if they choose three correct options. The knowledge
level was determined by converting the total scores into percentages and categorizing them as good knowledge (>75%), fair knowledge (60-75%), and poor knowledge (60%). Demographic factors included age (<30, 31-35, 36-45, 46-55, and >55), gender (male, female), qualification level (general physician, master in family medicine, family medicine specialist, family medicine consultant, and other), experience (0-2, 3-5, 6-10, >10 years), patients seen per week (0-20, 21-40, >40), SLE patients seen per year (0, 1-10, 11-20, >20), working at TCC for more than 20 years (Yes, No), and SLE patients seen per year (Yes, No). The one-way analysis of variance (ANOVA) test, the independent T-test, and the chi test were used to explore differences between participants' knowledge scores according to their socio-demographic characteristics. A P-value of 0.05 or less was considered statistically significant.

Results

We received 203 responses to the interview survey (a response rate of 77.18%). The participants' sociodemographic characteristics showed that 31.5% belonged to the age group of 35-45 years, 58.1% were males, 68.5% were GPs, and 38.9% had experience of more than ten years. The practice-related characteristics showed that 70.4% of the participants saw >40 patients per week; 55.2% reported that they saw 1-10 SLE patients in a year; 43.3% reported that they worked in a tertiary care center (TCC) for more than six months; and 11.8% worked in a rheumatology department (Table 1).
The assessment of knowledge related to SLE showed that 95.1% agreed that SLE is an autoimmune disease, and 83.3% responded that it affects females predominantly. The correct responses related to other knowledge items regarding SLE, its diagnosis, and management are given in Table 2.

### TABLE 1: Sociodemographic and practice-related characteristics

|                          | N   | %  |
|--------------------------|-----|----|
| Age (years)              |     |    |
| <30                      | 51  | 25.1|
| 31–35                    | 22  | 10.8|
| 36–45                    | 64  | 31.5|
| 46–55                    | 50  | 24.6|
| >55                      | 16  | 7.9 |
| Gender                   |     |    |
| Female                   | 85  | 41.9|
| Male                     | 118 | 58.1|
| Qualification level      |     |    |
| General physician        | 139 | 68.5|
| Master in family medicine| 23  | 11.3|
| Family medicine specialist| 23 | 11.3|
| Family medicine consultant| 14 | 6.9 |
| Others                   | 4   | 2.0 |
| Experience (years)       |     |    |
| 0–2                      | 41  | 20.2|
| 3–5                      | 34  | 16.7|
| 6–10                     | 49  | 24.1|
| >10                      | 79  | 38.9|
| Patients seen per week   |     |    |
| 0–20                     | 24  | 11.8|
| 21–40                    | 36  | 17.7|
| >40                      | 143 | 70.4|
| SLE\(^1\) patients seen per year |     |    |
| 0–20                     | 77  | 37.9|
| 1–10                     | 112 | 55.2|
| 11–20                    | 10  | 4.9 |
| >20                      | 4   | 2.0 |
| Worked at TCC\(^2\) for more than 6 months |     |    |
| No                       | 115 | 56.7|
| Yes                      | 88  | 43.3|
| Worked in a rheumatology department |     |    |
| No                       | 179 | 88.2|
| Yes                      | 24  | 11.8|

1\(^{\text{Systemic lupus erythematosus.}}\)
2\(^{\text{Tertiary care center.}}\)
SLE disease predominantly affect female gender 169 (83.3)
SLE disease commonly affecting patient between the age of 20 and 50 170 (83.7)
SLE can be induced with exposure to some of medications 156 (76.8)
Constitutional symptoms include (fatigue, fever, and weight loss) can be presented in SLE patient 181 (83.7)
SLE patients can present with renal manifestations like proteinuria and glomerulonephritis 191 (94.1)
SLE patients can present with serositis including pleural effusion, pericardial effusion, and pericarditis 163 (80.3)
SLE patients can present with musculoskeletal symptoms include (weakness, myalgia, arthralgia, arthritis, and morning stiffness) 188 (92.6)
SLE patients can present with cutaneous skin manifestation like alopecia, oral ulcers, and skin rash 190 (93.6)
SLE patients can present with hematological manifestations like (anemia and leukopenia) 163 (80.3)
Almost all patients of SLE present with neuropsychological symptoms like (delirium, seizures, and psychosis)* 102 (50.2)
SLE disease is not associated with antiphospholipid syndrome* 62 (30.5)
Know a lupus specific skin disease 78 (38.4)
Know the classification criteria for SLE 32 (15.8)
2019 EULAR/ACR² criteria that have high sensitivity for SLE classification 41 (20.2)
2019 EULAR/ACR criteria that have high specificity for SLE classification 45 (22.2)
Clinical scenario that is highly possible as SLE case 122 (60.1)
Screening test is recommended to use in suspected SLE case 148 (72.9)
Tests specific for SLE disease 23 (11.3)
Leukopenia, anemia, and thrombocytopenia are used as a marker of disease activity in SLE patients 117 (57.6)
Antinuclear antibodies is used as a marker of disease activity in SLE patients* 31 (15.3)
Anti-double strand DNA and complements level are used as a marker of disease activity in SLE patients 132 (65)
Raised creatinine level and presence of active sediments or proteins in urine sample is used as a marker of renal involvement in SLE patients 153 (75.4)
Treating patients with SLE in multidisciplinary clinics will lead to better outcomes than treating them by PHC provider alone 171 (84.2)
It's recommended to start CS⁴ therapy immediately in newly diagnosed SLE patients regardless their disease activity* 46 (22.7)
Anti-malarial medication like HCQ⁵ is recommended to all SLE patients due to mortality and morbidity benefit 143 (70.4)
Medications that is considered safe and should be continue during pregnancy in SLE patients 36 (17.7)
It is safe for SLE patients with quiescent disease to receive Covid-19 vaccine 126 (62.1)

**TABLE 2: Participants responses for knowledge-based items related to systemic lupus erythematosus (N=203)**

1Systemic lupus erythematosus.

²European League Against Rheumatism and the American College of Rheumatology.

³Primary health care.

⁴Corticosteroids.

⁵Hydroxychloroquine.

*Wrong answers.
The analysis showed that the mean knowledge score of the participants was 15.95 ± 4.12 (minimum: 0 and maximum: 25.25). Our study found that only 4.4% had good knowledge related to SLE, and nearly half of the participants (49.8%) had poor knowledge (Figure 1).

**FIGURE 1:** The knowledge level of the participants toward systemic lupus erythematosus, good knowledge (>75%), fair knowledge (60-75%), and poor knowledge (60% or lower).

The relationship between the knowledge level and various sociodemographic and practice-related characteristics is given in Table 3. It was found that participants who had the qualification level of family medicine specialist and family medicine consultant demonstrated comparatively higher knowledge than others, but without a significant difference (P = 0.068). The participants who had seen more than 40 patients per week showed better knowledge levels than those who had seen a lesser number of patients, however, without a significant difference (p = 0.448). The participants' age, gender, and other practice-related characteristics did not show any statistically significant differences in knowledge levels (Table 3).

| Knowledge     | Good | Fair | Poor |
|---------------|------|------|------|
| **Count**     |      |      |      |
| **Row N %**   |      |      |      |
| **Age (years)** |    |      |      |
| <30           | 4   | 16   | 31   | 60.8% |
| 31–35         | 1   | 9    | 12   | 54.5% |
| 36–45         | 2   | 31   | 31   | 48.4% |
| 46–55         | 2   | 31   | 17   | 34.0% |
| >55           | 0   | 6    | 10   | 62.5% |
| **Gender**    |    |      |      |
| Female        | 5   | 41   | 39   | 45.9% |
| Male          | 4   | 52   | 62   | 52.5% |

The p-values are shown in parentheses.
| Qualification level | General physician | Master in family medicine | Family medicine specialist | Family medicine consultant | Others |
|-------------------|-------------------|---------------------------|---------------------------|---------------------------|--------|
|                   | 7                 | 0                         | 2                         | 0                         | 0      |
|                   | 5.0%              | 0.0%                      | 8.7%                      | 0.0%                      | 0.0%   |
|                   | 57                | 11                        | 11                        | 13                        | 1      |
|                   | 41.0%             | 47.8%                     | 47.8%                     | 92.9%                     | 25.0%  |
|                   | 75                | 12                        | 10                        | 1                         | 3      |
|                   | 54.0%             | 52.2%                     | 43.5%                     | 7.1%                      | 75.0%  |

| Experience (years) | 0–2 | 3 | 7.3% | 13 | 31.7% | 25 | 61.0% | 0.116<sup>α</sup> |
|--------------------|-----|---|------|----|-------|----|-------|-----------------|
|                    | 7   | 2 | 5.9% | 12 | 35.3% | 20 | 58.8% |                 |
|                    | 1   | 1 | 2.0% | 21 | 42.9% | 27 | 55.1% |                 |
|                    | 5   | 3 | 3.8% | 47 | 59.5% | 29 | 36.7% |                 |

| Patients seen per week | 0–20 | 0 | 0.0% | 15 | 62.5% | 9 | 37.5% | 0.448<sup>α</sup> |
|------------------------|------|---|------|----|-------|---|-------|-----------------|
|                        | 21–40 | 4 | 11.1% | 8 | 22.2% | 24 | 66.7% |                 |
|                        | >40   | 5 | 3.5% | 70 | 49.0% | 68 | 47.6% |                 |

| SLE<sup>1</sup> patients seen per year | 0 | 1 | 1.3% | 32 | 41.6% | 44 | 57.1% | 0.201<sup>α</sup> |
|----------------------------------------|---|---|------|----|-------|----|-------|-----------------|
|                                       | 1–10 | 8 | 7.1% | 54 | 48.2% | 50 | 44.6% |                 |
|                                       | 11–20 | 0 | 0.0% | 5 | 50.0% | 5 | 50.0% |                 |
|                                       | >20 | 0 | 0.0% | 2 | 50.0% | 2 | 50.0% |                 |

| Worked at TCC<sup>2</sup> for more than 6 months | No | 7 | 6.1% | 45 | 39.1% | 63 | 54.8% | 0.062<sup>β</sup> |
|--------------------------------------------------|----|---|------|----|-------|----|-------|-----------------|
|                                                  | Yes | 2 | 2.3% | 48 | 54.5% | 38 | 43.2% | (5.57)<sup>β</sup> |

| Worked in a rheumatology department | No | 8 | 4.5% | 78 | 43.6% | 93 | 52.0% | 0.209<sup>β</sup> |
|-------------------------------------|----|---|------|----|-------|----|-------|-----------------|
|                                     | Yes | 1 | 4.2% | 15 | 62.5% | 8 | 33.3% | (3.13)<sup>β</sup> |

**TABLE 3: Knowledge levels and their relationship with sociodemographic and practice-related characteristics**

1<sup>Systemic lupus erythematosus.</sup>

2<sup>Tertiary care center.</sup>

<sup>α</sup>Bonferroni adjusted p-value (ANOVA test).

<sup>β</sup>P-value as calculated by Chi-test.

It was reported by 48.3% of the participants that they addressed the difficulty in diagnosing SLE patients, whereas those not specialized in family medicine significantly reported greater difficulty compared to others (p<0.05). It was also found that participants, those who had experience (less than five years) and those who had not worked in the rheumatology department before, had difficulty in diagnosing SLE (p<0.05). It was reported by 20.2% that they had difficulty in referring SLE patients to specialized centers, and this was significantly more seen in GPs than others (p<0.05) (Table 4).
The degree of comfort in treating SLE patients alone was measured using a scale of 0 to 5, where 0 showed “not comfortable” and 5 was “very comfortable.” The mean comfort score was found to be 2.14 ± 1.5. When we compared these scores between different age groups, it was found that participants aged 46-55 years had given significantly higher scores than others (p<0.05). The comfortableness scores were significantly higher among family medicine consultants (p<0.001), those who worked in a TCC for more than six months (p<0.001), and those who worked in a rheumatology department (p<0.05) (Table 5).
|                  | No. | Mean | Standard deviation | P-value |
|------------------|-----|------|--------------------|---------|
| **Age (years)**  |     |      |                    |         |
| <30              | 51  | 1.9  | 1.5                |         |
| 31–35            | 22  | 2.2  | 2.0                |         |
| 36–45            | 64  | 1.9  | 1.3                | 0.008*α |
| 46–55            | 50  | 2.8  | 1.4                |         |
| >55              | 16  | 1.9  | 1.0                |         |
| **Gender**       |     |      |                    |         |
| Female           | 85  | 2.0  | 1.5                | 0.242β  |
| Male             | 118 | 2.2  | 1.4                |         |
| **Qualification level** |     |      |                    |         |
| General physician| 139 | 2.1  | 1.5                |         |
| Master in family medicine | 23  | 1.5  | 1.0                |         |
| Family medicine specialist | 23  | 1.8  | 1.1                | 0.000*α |
| Family medicine consultant | 14  | 4.1  | .8                 |         |
| Others           | 4   | 1.8  | 1.5                |         |
| **Experience (years)** |     |      |                    |         |
| 0–2              | 41  | 2.0  | 1.7                | 0.853α  |
| 3–5              | 34  | 2.1  | 1.3                |         |
| 6–10             | 49  | 2.1  | 1.5                |         |
| >10              | 79  | 2.3  | 1.4                |         |
| 0–20             | 24  | 2.0  | 1.3                |         |
| 21–40            | 36  | 2.0  | 1.3                | 0.732α  |
| >40              | 143 | 2.2  | 1.5                |         |
| **Patients seen per week** |     |      |                    |         |
| 0                | 77  | 2.0  | 1.5                |         |
| 1–10             | 112 | 2.2  | 1.5                |         |
| 11–20            | 10  | 2.1  | 1.0                |         |
| >20              | 4   | 2.3  | 1.7                |         |
| **SLE\(^1\) patients seen per year** |     |      |                    |         |
| 0                | 112 | 2.2  | 1.5                | 0.840α  |
| 1–10             | 112 | 2.2  | 1.5                |         |
| 11–20            | 10  | 2.1  | 1.0                |         |
| >20              | 4   | 2.3  | 1.7                |         |
| **Worked at TCC\(^2\) for more than 6 months** |     |      |                    |         |
| No               | 115 | 1.7  | 1.4                | 0.001*β |
| Yes              | 88  | 2.7  | 1.4                |         |
| **Worked in a rheumatology department** |     |      |                    |         |
| No               | 179 | 2.1  | 1.5                | 0.014*β |
| Yes              | 24  | 2.8  | 1.2                |         |

**TABLE 5: Comparison of comfortableness in treating SLE patients alone**

\(^1\)Systemic lupus erythematosus.

\(^2\)Tertiary care center.

*Significant at p-value <0.05.

\(^α\)ANOVA test Bonferroni corrected P-value.

\(^β\)t-test P-value.
diagnosis and management of SLE patients, coordination between rheumatologists and specialists from patients with SLE compared to GPs and other practitioners. To overcome ambiguities and challenges in the diagnosis of SLE, the awareness of PHCPs of SLE classification criteria is essential. The 2019-EULAR/ACR criterion has shown high sensitivity and specificity for SLE classification compared to the ACR-1997 and SLICC-2012 criteria. Our analysis showed that only 20.2% and 22.2% correctly identified the same sensitivity and specificity of the 2019-EULAR/ACR criterion, respectively. The immunological hallmark of SLE is ANA positivity, which is primarily used for screening purposes, and the pattern of autoantibodies expressed by individuals with this prototypic autoimmune disease is highly distinctive. In our survey, 15.5% of participants believed that ANA was employed as a measure of disease activity rather than a screening test in SLE patients. In primary health care, the diagnosis of SLE is often challenging because of many non-specific symptoms such as fatigue, rash, joint pain, etc. The biomarkers are often negative or normal in the early course of the disease. Approximately 90% of SLE patients experience constitutional symptoms such as fatigue, weight loss, and fever without a focal infection. Other common manifestations seen in most patients include arthralgia and myalgia. Malar rash and photosensitivity are reported to be present in 31% and 23%, respectively. Other uncommon manifestations include the Raynaud phenomenon, pleuritic chest pain, and mouth sores. The analysis showed that participants who had more experience and practitioners who had a history of working in the rheumatology department and TCC for more than six months demonstrated more comfort in treating SLE patients than others. It is reported that there is a paucity of specific understanding of SLE by family physicians and a need for more cohesive health care. There is a scarcity of studies exploring how GPs and PHCPs refer to and write prescriptions for SLE management. Patients with SLE may have diagnostic and treatment challenges due to regional variations in the availability and accessibility of rheumatologists, as well as an overall shortage of rheumatologists. To optimize chronic care and preventive health services for these patients, well-coordinated multidisciplinary healthcare teams comprised of subspecialists and family doctors are essential. ACR recommends that PHCPs and GPs understand the symptoms of SLE to aid in early diagnosis, treat and monitor patients with mild disease, acknowledge warning signs to accurately refer to a rheumatologist, and assist in evaluating clinical symptoms and therapeutic interventions in patients with moderate to severe disease.

Study limitations
Our study poses some limitations. First, the study only evaluated the level of knowledge without assessing its influence on the attitude of participants’ practice, which could reduce the reliability of the findings. However, to the best of our knowledge, this was the first study done in KSA to assess the knowledge of PHCPs and comfort regarding SLE diagnosis, its management, and referrals. Second, we were unable to verify if the respondents were demographically representative of the total sample. We encourage future research on this topic to include practitioners from all provinces in KSA as well as investigate areas of study limitations

Conclusions
This study showed that knowledge regarding SLE, its diagnosis, and management was not that satisfactory among the PHCPs. Family medicine consultants showed significantly higher levels of comfort in treating patients with SLE compared to GPs and other practitioners. To overcome ambiguities and challenges in the diagnosis and management of SLE patients, coordination between rheumatologists and specialists from
different disciplines at primary, secondary, and tertiary levels of care is of paramount importance. The role of PHCPs is crucial in diagnosing both mild and severe SLE manifestations and guiding these patients, minimizing the community’s disease burden.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Deanship of Scientific Research, Qassim University issued approval 1445-252680. Permission from Al Qassim health affairs directorate was obtained with an ethical approval number (1445-252680). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICME uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

The authors would like to thank the Deanship of Scientific Research, Qassim University for funding the publication of this project.

References

1. Choi J, Kim ST, Craft J: The pathogenesis of systemic lupus erythematosus—an update. Curr Opin Immunol. 2012, 24:651-7. 10.1016/j.coi.2012.10.004
2. Al-Arfaaj AS, Al-Balla SR, Al-Dalaan AN, Al-Saleh SS, Bababi SA, Mousa MM, Sekeit MA: Prevalence of systemic lupus erythematosus in central Saudi Arabia. Saud Med J. 2002, 23:87-89.
3. Metry AM, Al Salimi I, Al Balushi F, Youssef MA, Al Ismaili F, Hola A, Hannawi S: Systemic lupus erythematosus: symptoms and signs at initial presentations. Antiinflamm Antiallergy Agents Med Chem. 2019, 18:142-50. 10.2174/1871523018666181128161828
4. Cojocaru M, Cojocaru IM, Silosi I, Viabile CD: Manifestations of systemic lupus erythematosus. Med. 2011, 6:530-6.
5. Aringer M, Costenbader K, Dalikh D, et al.: 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019, 71:1400-12. 10.1002/art.40950
6. Fanourakis A, Tziolos N, Bertsias G, Boumpas DT: Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021, 80:14-25. 10.1136/annrheumdis-2020-218272
7. Oglesby A, Korves C, Lalive R, et al.: Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy. 2014, 12:179-90. 10.1007/s40258-014-0085-x
8. Feng X, Zou Y, Pan W, et al.: Associations of clinical features and prognosis with age at disease onset in patients with systemic lupus erythematosus. Lupus. 2014, 23:527-34. 10.1177/0961203313515308
9. Essadie M, Mackenzie T, Barré P, et al.: Can experienced clinicians predict the outcome of lupus nephritis?. Lupus. 1992, 1:205-14. 10.1016/0961-2033(92)90040-I
10. Lu X, Gu Y, Wang Y, Chen S, Ye S: Prognostic factors of lupus myelopathy. Lupus. 2008, 17:323-8. 10.1177/1029913X08080053
11. Faurchou M, Dreyer I, Kamper AL, Starklint H, Jacobsen S: Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res (Hoboken). 2010, 62:875-80. 10.1002/acr.20116
12. Piga M, Florio A, Cappelazzu G, Chessa E, Cangia M, Mathieu A, Cappelazzu G, Mathieu A, Cappelazzu G, Mathieu A, Cappelazzu G, Mathieu A, Cappelazzu G, Mathieu A, Cappelazzu G, Mathieu A: Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther. 2017, 19:247. 10.1186/s13075-017-1451-5
13. Urowitz M, Gladman DD, Ibáñez D, et al.: Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014, 66:1374-9. 10.1002/art.34229
14. Gergianakis I, Bertsias G: Systemic lupus erythematosus in primary care: an update and practical messages for the general practitioner. Front Med (Lausanne). 2018, 5:161. 10.5381/fmed.2018.0161
15. Blauw AA, Schuurh SW, van der Vleuten CP, Smits F, van der Linden S: Assessing clinical competence: recognition of case descriptions of rheumatic diseases by general practitioners. Br J Rheumatol. 1995, 34:575-7. 10.1093/rheumatology/34.4.575
16. Azon-Kouanou A, Aboué N, Missiho M, et al.: Knowledge of general practitioners in Cotonou about systemic lupus erythematosus. Open J Intern Med. 2020, 10:311-320. 10.4236/ojim.2020.104052
17. Wang XD, Sha Y, Xu D, Chen JJ: Systemic lupus erythematosus: what do Chinese patients and general practitioners know? [PREPRINT]. Res Square. 2020, 20210205/v3, 5. 10.21205/rs.3/v5-25287/v1
18. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y: Systemic lupus erythematosus one disease or many?. Autoimmun Rev. 2012, 11:593-5. 10.1016/j.autrev.2011.10.020
19. Arat S, Lenaerts JL, De Lange E, et al.: Illness representations of systemic lupus erythematosus and systemic sclerosis: a comparison of patients, their rheumatologists and their general practitioners. Lupus Sci Med. 2017, 4:e000232. 10.1136/lupus-2017-000232
20. Rat AC, Henequari V, Boissier MC: Do primary care physicians have a place in the management of rheumatoid arthritis? Joint Bone Spine. 2004, 71:190-7. 10.1016/j.jbspin.2003.09.003
21. Aljohani R, Gladman DD, Su J, Urowitz MB: Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. Clin Rheumatol. 2017, 36:1773-8. 10.1007/s10067-017-7115-7
22. Tan EM, Cohen AS, Fries JF, et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25:1271-7. 10.1002/art.1780251101
23. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40:1725. 10.1002/art.1780400928
24. Tešija Kuna A, Dvrat V, Kozmar A, Gugo K: Assessment of antinuclear antibodies (ANA): national recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine. Biochem Med (Zagreb). 2021, 31:020502. 10.11613/BM.2021.020502
25. Aringer M, Petri M: New classification criteria for systemic lupus erythematosus. Curr Opin Rheumatol. 2020, 32:590-6. 10.1097/BOR.0000000000001070
26. Agmon-Levin N, Danoiseaux J, Kallenberg C, et al.: International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014, 73:17-23. 10.1136/annrheumdis-2013-203863
27. Pisetsky DS: Antinuclear antibody testing - misunderstood or misbegotten? Nat Rev Rheumatol. 2017, 13:495-502. 10.1038/nrrheum.2017.74
28. Zonana-Nacach A, Roseman JM, McGwin G Jr, Friedman AW, Baethge BA, Reveille JD, Alarcón GS: Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. Lupus. 2000, 9:101-9. 10.1191/096120300678210446
29. Zoma A: Musculoskeletal involvement in systemic lupus erythematosus. Lupus. 2004, 13:851-3. 10.1191/0961203304lu2031oa
30. Cervera R, Khamashia MA, Font J, et al.: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003, 82:299-308. 10.1097/01.md.0000091181.95122.55
31. Hale ED, Trebarne GJ, Lyons AC, et al.: “Joining the dots” for patients with systemic lupus erythematosus: personal perspectives of health care from a qualitative study. Ann Rheum Dis. 2006, 65:285-9. 10.1136/ard.2005.057077
32. FitzGerald JD, Battistone M, Brown CR Jr, et al.: Regional distribution of adult rheumatologists. Arthritis Rheum. 2015, 65:3017-25. 10.1002/art.38167
33. Deal CL, Hooker R, Harrington T, et al.: The United States rheumatology workforce: supply and demand, 2005-2025. Arthritis Rheum. 2007, 56:722-9. 10.1002/art.22437
34. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum. 1999, 42:1785-1796. 10.1002/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-%23